No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AUTL Autolus Therapeutics
- 4.710
- -0.090-1.88%
Trading Apr 19 12:06 ET
1.25BMarket Cap-3925P/E (TTM)
4.840High4.660Low207.48KVolume4.750Open4.800Pre Close982.33KTurnover0.23%Turnover RatioLossP/E (Static)265.93MShares7.45052wk High11.24P/B429.44MFloat Cap1.61052wk Low--Dividend TTM91.18MShs Float53.240Historical High--Div YieldTTM3.75%Amplitude1.600Historical Low4.734Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
European equities traded in the US as American depositary receipts were treading water in Thursday morning session, nudging 0.006% higher to 1,330.06 on the S&P Europe Select ADR Index. From continent
Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook
Express News | Needham Reiterates Buy on Autolus Therapeutics, Maintains $9 Price Target
GLYC, APLD and AUTL Are Among After Hour Movers
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%
Comments
Upcoming Cell & Gene Therapy PDUFA’s in 2024
Several highly anticipated PDUFA decisions are approaching..👇
Abeona Therapeutics ($Abeona Therapeutics(ABEO.US$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ($Rocket Pharmaceuticals(RCKT.US$ )...
Abeona Therapeutics ($Abeona Therapeutics(ABEO.US$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ($Rocket Pharmaceuticals(RCKT.US$ )...
6
The appointment of Robert W. Azelby, with his extensive experience and track record in building successful biotech companies, is seen as a valuable addition to Autolus's Board as the company moves closer to commercializing its first product.
The significant increase in Autolus Therapeutics' share price and revenue growth has caught the market's attention, signalling optimism. However, despite recent positive returns, the company's long-term loss requires cautious investment consideration.
Dr. Christian Itin, CEO of Autolus, expressed optimism about Leiderman's appointment citing her vast financial, transaction, and operational experience. He also shared the company's anticipation to transition from a development stage to a commercial entity.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg